Company intelligence / Profile preview
Arachos Pharma Ltd
- Ownership
- Private
- Development stage
- Preclinical
Overview
The company was developing AP362, an oral selective glucocorticoid receptor modulator with initial data indicating powerful anti-inflammatory action with fewer side effects than conventional therapies. The company was dissolved in 2014 before completing clinical trials.
- Therapeutic areas
- PulmonologyDermatologyImmunology
- Modalities
- Small molecules
- Industry
- Biotech
Drug pipeline
1 assetBeyond the preview
Go deeper on Arachos Pharma Ltd.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Arachos Pharma Ltd.